A double-blind, randomized, placebo-controlled study to assess the efficacy of XXXX for reducing the risk of @entity43 .

@entity43 @entity3102 @entity1 @entity3610
OBJECTIVE: To evaluate the role of @entity3102 in prevention of @entity43 ( @entity43 ) in @entity1 with the @entity3610 ( @entity3610 ) undergoing ovarian stimulation with gonadotropins. DESIGN: Prospective, randomized, double-blind, placebo-controlled study. SETTING: University hospitals. One hundred nine @entity1 with @entity3610 who were referred for treatment with gonadotropins. INTERVENTION(S): Fifty @entity1 were randomly assigned to receive two ampoules of hMG beginning on day 2 or 3 of the cycle and @entity3102 (50 mg every 48 hours) starting on the first day of hMG treatment. Fifty-one @entity1 received the same amount of hMG plus one tablet of placebo every 48 hours. MAIN OUTCOME MEASURE(S): Follicular development, E(2) level, and pregnancy rate. RESULT(S): The total number of hMG ampoules and duration of treatment to attain ovarian stimulation were higher among @entity3102 recipients. The serum E(2) level and number of @entity1 with dominant follicles on day 9 of the cycle were greater in placebo recipients. Serum E(2) level and total number of follicles at the time of hCG administration did not differ between the two groups. The cancellation rate and @entity43 rate were similar in the two groups. CONCLUSION(S): @entity3102 does not prevent @entity43 in @entity1 with @entity3610 who are undergoing ovarian stimulation. It may reduce the rate of folliculogenesis and steroidogenesis.
